The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies
Standard
The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies. / Behrmann, Lena; Wellbrock, Jasmin; Fiedler, Walter.
in: EXPERT OPIN THER TAR, Jahrgang 24, Nr. 5, 05.2020, S. 451-462.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies
AU - Behrmann, Lena
AU - Wellbrock, Jasmin
AU - Fiedler, Walter
PY - 2020/5
Y1 - 2020/5
N2 - Introduction: Myeloid malignancies are caused by uncontrolled proliferation of neoplastic cells and lack of mature hematopoietic cells. Beside intrinsic genetic and epigenetic alterations within the neoplastic population, abnormal function of the bone marrow stroma promotes the neoplastic process. To overcome the supportive action of the microenvironment, recent research focuses on the development of targeted therapies, inhibiting the interaction of malignant cells and niche cells.Areas covered: This review covers regulatory networks and potential druggable pathways within the hematopoietic stem cell niche. Recent insights into the cell-to-cell interactions in the bone marrow microenvironment are presented. We performed literature searches using PubMed Database from 2000 to the present.Expert opinion: Future therapy of myeloid malignancies must focus on targeted, personalized treatment addressing specific alterations within the malignant and the supporting niche cells. This includes treatments to overcome resistance mechanisms against chemotherapeutic agents mediated by supporting microenvironment. Novel techniques employing sequencing approaches, Crisp/Cas9, or transgenic mouse models are required to elucidate specific interactions between components of the bone marrow niche to identify new therapeutic targets.
AB - Introduction: Myeloid malignancies are caused by uncontrolled proliferation of neoplastic cells and lack of mature hematopoietic cells. Beside intrinsic genetic and epigenetic alterations within the neoplastic population, abnormal function of the bone marrow stroma promotes the neoplastic process. To overcome the supportive action of the microenvironment, recent research focuses on the development of targeted therapies, inhibiting the interaction of malignant cells and niche cells.Areas covered: This review covers regulatory networks and potential druggable pathways within the hematopoietic stem cell niche. Recent insights into the cell-to-cell interactions in the bone marrow microenvironment are presented. We performed literature searches using PubMed Database from 2000 to the present.Expert opinion: Future therapy of myeloid malignancies must focus on targeted, personalized treatment addressing specific alterations within the malignant and the supporting niche cells. This includes treatments to overcome resistance mechanisms against chemotherapeutic agents mediated by supporting microenvironment. Novel techniques employing sequencing approaches, Crisp/Cas9, or transgenic mouse models are required to elucidate specific interactions between components of the bone marrow niche to identify new therapeutic targets.
KW - Animals
KW - Antineoplastic Agents/pharmacology
KW - Bone Marrow Cells/cytology
KW - Hematologic Neoplasms/pathology
KW - Humans
KW - Mice
KW - Mice, Transgenic
KW - Molecular Targeted Therapy
KW - Myeloproliferative Disorders/pathology
KW - Stem Cell Niche/physiology
KW - Stromal Cells/cytology
KW - Tumor Microenvironment
U2 - 10.1080/14728222.2020.1744850
DO - 10.1080/14728222.2020.1744850
M3 - SCORING: Review article
C2 - 32188313
VL - 24
SP - 451
EP - 462
JO - EXPERT OPIN THER TAR
JF - EXPERT OPIN THER TAR
SN - 1472-8222
IS - 5
ER -
